Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

2193 - Adherence to ESMO 2014 guidelines on bone-targeting agent (BTA) initiation for breast and prostate cancer patients: real-world insights from practicing European physicians

Date

28 Sep 2019

Session

Poster Display session 1

Presenters

Alex Rider

Citation

Annals of Oncology (2019) 30 (suppl_5): v718-v746. 10.1093/annonc/mdz265

Authors

A. Rider1, A.M. Seesaghur2, K. Lewis3, D. Bluff3, A. Marongiu2, G. Demonty4

Author affiliations

  • 1 Adelphi Real World, Adelphi Group Ltd, 000 - Cheshire/GB
  • 2 Centre For Observational Research, Amgen Ltd, UB8 1DH - Uxbridge/GB
  • 3 Adelphi Real World, Adelphi Group Ltd, Cheshire/GB
  • 4 European Medical, Amgen GmbH, Rotkreuz/CH
More

Resources

Abstract 2193

Background

Despite existing clinical guidelines on bone health in patients with cancer (ESMO 2014), the use of recommended BTA is sub-optimal for many patients. It is unclear if physicians’ decisions are aligned with ESMO’s guidelines to initiate BTA as soon as bone metastasis (BM) are diagnosed, irrespective of symptomatic disease, in breast cancer (BC) or castration-resistant prostate cancer (CRPC) patients. The current study describes BTA initiation in BC or CRPC patients with BM treated within routine clinical settings.

Methods

Data reported by physicians (oncologists or urologists) in Europe via online data capture using physician-directed surveys and patients’ medical records as required were analysed. Adult BC or physician-defined CRPC patients included in the study received active anti-cancer treatment between February 2015 and April 2015. Adherence to the ESMO 2014 guidelines was defined as the proportion of patients with a BTA initiation within 3 months (<90 days) of BM diagnosis.

Results

A total of 731 physicians reported data on 1,857 patients treated for their cancer in Europe. For BC patients (n = 1,195) and CRPC patients (n = 662) treated by oncologists, only 84% and 61%, respectively, received their first BTA within 3 months of BM diagnosis. Adherence to the ESMO 2014 guidelines was lower (55%) in the 118 urologist-treated CRPC patients. Most physicians (87%) across all specialties considered the presence or absence of bone pain as the most important factor when assessing the risk of bone complications. Bone pain was also reported by the physicians as a main reason for BTA initiation in nearly three-quarters of BTA-treated patients (71% BC, 75% CRPC). Overall, 56% of physicians considered bone pain to be either a bone complication (58% oncologists vs 48% urologists) or a skeletal-related event (53% oncologists vs 68% urologists).

Conclusions

Adherence to ESMO’s guidelines on bone health differed by tumour type and by physician specialty within solid tumour patients treated in routine clinical settings. Despite ESMO’s guidance on bone protection irrespective of symptomatic disease, bone pain appeared to be a trigger for BTA initiation in routine clinical practice.

Clinical trial identification

Amgen study 20150107.

Editorial acknowledgement

Legal entity responsible for the study

Amgen (Europe) GmbH.

Funding

Amgen (Europe) GmbH.

Disclosure

A. Rider: Full / Part-time employment: Adelphi Group Ltd. A.M. Seesaghur: Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen; Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen. K. Lewis: Full / Part-time employment: Adelphi Group Ltd. D. Bluff: Full / Part-time employment: Adelphi Group Ltd. A. Marongiu: Full / Part-time employment, Andrea Marongiu is a contract worker at Amgen. G. Demonty: Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings